FDA Clears Blood Test for Alzheimer's Amyloid Pathology Detection

The U.S. Food and Drug Administration has cleared a new blood test designed to help identify amyloid pathology associated with Alzheimer's disease in adults with cognitive symptoms. The test, called Elecsys pTau217, was developed by Roche in collaboration with Eli Lilly and announced on August 25, 2026. It is intended for use in individuals aged 55 and older who are experiencing signs or symptoms of cognitive decline.

The clearance marks a significant development in the field of Alzheimer's diagnostics, offering a less invasive and more accessible alternative to traditional methods like PET scans or cerebrospinal fluid analysis. The Elecsys pTau217 test measures levels of phosphorylated tau 217, a protein fragment in the blood that correlates with the presence of amyloid plaques and tau tangles in the brain. According to Roche, the test demonstrated high agreement with amyloid PET imaging in clinical evaluations.

The test is designed to support both rule-in and rule-out assessments of amyloid pathology using a single biomarker and validated clinical cutoffs. This approach aims to simplify laboratory testing and make the diagnostic process more efficient in both primary care and...